Quanticate
The data-focused CRO has named David Hukin as the company's new senior director of pharmacovigilance (PV) reporting to the chief operating officer Alan Morgan.
Hukin – who has a PhD in cell physiology and biophysics – is based in the UK will take responsibility for growing Quanticate’s existing PV capabilities.
The company last year upgraded its PV database and in-house technology to prepare for the Article 2(3) of Directive 2010/84/EU deadline.
According to the UK-based CRO, the investment anticipates the launch of an improved version of EudraVigilance – the European Medicines Agency’s (EMA) system for managing and analyzing information on suspected adverse reactions to medicines.